Pan-HSV-2 IgG Antibody in Vaccinated Mice and Guinea Pigs Correlates with Protection against Herpes Simplex Virus 2

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Halford, William P ^a   Geltz, Joshua ^a   Gershburg, Edward ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; HERPES SIMPLEX VACCINE; HERPEVAC; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; PHOSPHORYL LIPID A; RECOMBINANT GLYCOPROTEIN D 2 ANTIGEN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EYE INFECTION; GENITAL HERPES; GUINEA PIG; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; IMMUNITY; MOUSE; NONHUMAN; SURVIVAL RATE; VACCINATION; VIRUS SHEDDING; ANIMAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY;

ANIMALIA; CAVIA; HERPES; HUMAN HERPESVIRUS 2; MUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GUINEA PIGS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; IMMUNOGLOBULIN G; MICE;

EID: 84878776615     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065523     Document Type: Article

References (80)

1. Shlapobersky M, Marshak JO, Dong L, Huang ML, Wei Q, et al. (2012) Vaxfectin(R)-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. J Gen Virol 93: 1305-1315.
2. Bernstein DI, Farley N, Bravo FJ, Earwood J, McNeal M, et al. (2010) The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine 28: 3748-3753.
3. Bourne N, Milligan GN, Stanberry LR, Stegall R, Pyles RB, (2005) Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis 192: 2117-2123.
4. Bernstein D, (2005) Glycoprotein D adjuvant herpes simplex virus vaccine. Expert Rev Vaccines 4: 615-627.
5. Bourne N, Bravo FJ, Francotte M, Bernstein DI, Myers MG, et al. (2003) Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis 187: 542-549.
6. Khodai T, Chappell D, Christy C, Cockle P, Eyles J, et al. (2011) Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models. Clin Vaccine Immunol 18: 1702-1709.
7. Bernstein DI, Earwood JD, Bravo FJ, Cohen GH, Eisenberg RJ, et al. (2011) Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig. Vaccine 29: 2071-2078.
8. Allen EM, Weir JP, Martin S, Mercadal C, Rouse BT, (1990) Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity. Viral Immunol 3: 207-215.
9. Weir JP, Bennett M, Allen EM, Elkins KL, Martin S, et al. (1989) Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge. J Gen Virol 70 (Pt 10): 2587-2594.
10. Kuklin N, Daheshia M, Karem K, Manickan E, Rouse BT, (1997) Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J Virol 71: 3138-3145.
11. Manickan E, Francotte M, Kuklin N, Dewerchin M, Molitor C, et al. (1995) Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells. J Virol 69: 4711-4716.
12. Eo SK, Gierynska M, Kamar AA, Rouse BT, (2001) Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J Immunol 166: 5473-5479.
13. Natuk RJ, Cooper D, Guo M, Calderon P, Wright KJ, et al. (2006) Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. J Virol 80: 4447-4457.
14. Orr MT, Orgun NN, Wilson CB, Way SS, (2007) Cutting Edge: Recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection. J Immunol 178: 4731-4735.
15. Karem KL, Bowen J, Kuklin N, Rouse BT, (1997) Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens. J Gen Virol 78 (Pt 2): 427-434.
16. Brans R, Yao F, (2010) Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs. BMC Microbiology 10: 163.
17. Meignier B, Longnecker R, Roizman B, (1988) In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 158: 602-614.
18. Morello CS, Kraynyak KA, Levinson MS, Chen Z, Lee KF, et al. (2012) Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine 30: 6541-6550.
19. Skinner GR, Williams DR, Buchan A, Whitney J, Harding M, et al. (1978) Preparation and efficacy of an inactivated subunit vaccine (NFUIBHK) against type 2 Herpes simplex virus infection. Med Microbiol Immunol 166: 119-132.
20. Skinner GR, Turyk ME, Benson CA, Wilbanks GD, Heseltine P, et al. (1997) The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial. Med Microbiol Immunol (Berl) 186: 31-36.
21. Skinner GR, Fink C, Melling J, Wiblin C, Thornton B, et al. (1992) Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis. Med Microbiol Immunol 180: 305-320.
22. Morrison LA, Da Costa XJ, Knipe DM, (1998) Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology 243: 178-187.
23. Hoshino Y, Pesnicak L, Dowdell KC, Lacayo J, Dudek T, et al. (2008) Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 26: 4034-4040.
24. Aurelian L, Kokuba H, Smith CC, (1999) Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Vaccine 17: 1951-1963.
25. Gyotoku T, Ono F, Aurelian L, (2002) Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK. Vaccine 20: 2796-2807.
26. Brittle EE, Wang F, Lubinski JM, Bunte RM, Friedman HM, (2008) A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine. J Virol 82: 8431-8441.
27. Prichard MN, Kaiwar R, Jackman WT, Quenelle DC, Collins DJ, et al. (2005) Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 23: 5424-5431.
28. Schrimpf JE, Tu EM, Wang H, Wong YM, Morrison LA, (2011) B7 costimulation molecules encoded by replication-defective, vhs-deficient HSV-1 improve vaccine-induced protection against corneal disease. PLoS ONE 6: e22772.
29. Halford WP, Puschel R, Gershburg E, Wilber A, Gershburg S, et al. (2011) A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS ONE 6: e17748.
30. Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, et al. (2012) Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. J Virol 86: 4586-4598.
31. Delagrave S, Hernandez H, Zhou C, Hamberger JF, Mundle ST, et al. (2012) Immunogenicity and Efficacy of Intramuscular Replication-Defective and Subunit Vaccines against Herpes Simplex Virus Type 2 in the Mouse Genital Model. PLoS ONE 7: e46714.
32. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, et al. (2012) Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 366: 34-43.
33. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, et al. (2002) Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347: 1652-1661.
34. Straus SE, Wald A, Kost RG, McKenzie R, Langenberg AG, et al. (1997) Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 176: 1129-1134.
35. Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, et al. (1999) Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282: 331-340.
36. Straus SE, Corey L, Burke RL, Savarese B, Barnum G, et al. (1994) Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343: 1460-1463.
37. Mertz GJ, Ashley R, Burke RL, Benedetti J, Critchlow C, et al. (1990) Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 161: 653-660.
38. Cohen J, (2010) Immunology. Painful failure of promising genital herpes vaccine. Science 330: 304.
39. Ledford H (2012) Failed herpes vaccine puzzles virologists. Nature. pp. doi:10.1038/nature.2012.9739.
40. Whitley RJ, Roizman B, (2002) Herpes simplex viruses: is a vaccine tenable? J Clin Invest 110: 145-151.
41. Dropulic LK, Cohen JI, (2012) The challenge of developing a herpes simplex virus 2 vaccine. Expert Rev Vaccines 11: 1429-1440.
42. Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, et al. (1998) Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 101: 1500-1508.
43. Halford WP, Gebhardt BM (2011) Host interferon: a silent partner in the regulation of herpes simplex virus latency. In: Mossman KL, editor. Viruses and Interferon: current research. Hethersett, UK: Horizon Scientific Press. 85-11.
44. Divito S, Cherpes TL, Hendricks RL, (2006) A triple entente: virus, neurons, and CD8+ T cells maintain HSV-1 latency. Immunol Res 36: 119-126.
45. Khanna KM, Lepisto AJ, Hendricks RL, (2004) Immunity to latent viral infection: many skirmishes but few fatalities. Trends Immunol 25: 230-234.
46. Amanna IJ, Messaoudi I, Slifka MK, (2008) Protective immunity following vaccination: how is it defined? Hum Vaccin 4: 316-319.
47. Shin H, Iwasaki A, (2012) A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 491: 463-467.
48. Rouse BT, Kaistha SD, (2006) A tale of 2 alpha-herpesviruses: lessons for vaccinologists. Clin Infect Dis 42: 810-817.
49. Hosken N, McGowan P, Meier A, Koelle DM, Sleath P, et al. (2006) Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J Virol 80: 5509-5515.
50. Khanna K, Bonneau R, Kinchington P, Hendricks R, (2003) Herpes simplex virus-specific memory CD8(+) T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 18: 593-603.
51. Laing KJ, Magaret AS, Mueller DE, Zhao L, Johnston C, et al. (2010) Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. J Clin Immunol 30: 703-722.
52. Gilman SC, Docherty JJ, Rawls WE, (1981) Antibody responses in humans to individual proteins of herpes simplex viruses. Infect Immun 34: 880-887.
53. Halford WP, Puschel R, Rakowski B, (2010) Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine. PLoS ONE 5: e12251.
54. Nicola AV, Willis SH, Naidoo NN, Eisenberg RJ, Cohen GH, (1996) Structure-function analysis of soluble forms of herpes simplex virus glycoprotein D. J Virol. 70: 3815-3822.
55. St Leger AJ, Peters B, Sidney J, Sette A, Hendricks RL, (2011) Defining the herpes simplex virus-specific CD8+ T cell repertoire in C57BL/6 mice. J Immunol 186: 3927-3933.
56. Posavad CM, Remington M, Mueller DE, Zhao L, Magaret AS, et al. (2010) Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol 184: 3250-3259.
57. Tirabassi RS, Ace CI, Levchenko T, Torchilin VP, Selin LK, et al. (2011) A mucosal vaccination approach for herpes simplex virus type 2. Vaccine 29: 1090-1098.
58. Oakes JE, (1975) Role for cell-mediated immunity in the resistance of mice to subcutaneous herpes simplex virus infection. Infect Immun 12: 166-172.
59. Nagafuchi S, Oda H, Mori R, Taniguchi T, (1979) Mechanism of acquired resistance to herpes simplex virus infection as studied in nude mice. J Gen Virol 44: 715-723.
60. Halford WP, Maender JL, Gebhardt BM, (2005) Re-evaluating the role of natural killer cells in innate resistance to herpes simplex virus type 1. Virol J 2: 56.
61. Knickelbein JE, Khanna KM, Yee MB, Baty CJ, Kinchington PR, et al. (2008) Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 322: 268-271.
62. Theil D, Derfuss T, Paripovic I, Herberger S, Meinl E, et al. (2003) Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am J Pathol 163: 2179-2184.
63. Liu T, Khanna KM, Chen X, Fink DJ, Hendricks RL, (2000) CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med 191: 1459-1466.
64. Simmons A, Tscharke DC, (1992) Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: implications for the fate of virally infected neurons. J Exp Med 175: 1337-1344.
65. Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, et al. (2007) Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 204: 595-603.
66. Koelle DM, Corey L, (2008) Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med 59: 381-395.
67. Johnston C, Koelle DM, Wald A, (2012) HSV-2: in pursuit of a vaccine. J Clin Invest 121: 4600-4609.
68. Laing KJ, Dong L, Sidney J, Sette A, Koelle DM, (2012) Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses. Clin Exp Immunol 167: 47-58.
69. Dudek T, Knipe DM, (2006) Replication-defective viruses as vaccines and vaccine vectors. Virology 344: 230-239.
70. Morrison LA, (2002) Vaccines against genital herpes: progress and limitations. Drugs 62: 1119-1129.
71. Morrison LA, Zhu L, Thebeau LG, (2001) Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. J Virol 75: 1195-1204.
72. Chu CF, Meador MG, Young CG, Strasser JE, Bourne N, et al. (2008) Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and-independent mechanisms. J Reprod Immunol 78: 58-67.
73. Staats HF, Oakes JE, Lausch RN, (1991) Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells. J Virol 65: 6008-6014.
74. Mackay LK, Stock AT, Ma JZ, Jones CM, Kent SJ, et al. (2012) Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci U S A 109: 7037-7042.
75. Chentoufi AA, Dasgupta G, Christensen ND, Hu J, Choudhury ZS, et al. (2010) A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes. J Immunol 184: 2561-2571.
76. McClements WL, Armstrong ME, Keys RD, Liu MA, (1996) Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci U S A 93: 11414-11420.
77. Pyles RB, Higgins D, Chalk C, Zalar A, Eiden J, et al. (2002) Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol 76: 11387-11396.
78. Samaniego LA, Neiderhiser L, DeLuca NA, (1998) Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 72: 3307-3320.
79. Halford WP, Halford KJ, Pierce AT, (2005) Mathematical analysis demonstrates that interferons-beta and-gamma interact in a multiplicative manner to disrupt herpes simplex virus replication. J Theor Biol 235: 439-454.
80. Preacher KJ, Briggs NE (2001) Calculation for Fisher's Exact Test: An interactive calculation tool for Fisher's exact probability test for 2×2 tables [Computer software].